- Home
- INO vs JSPR Comparison
INO vs JSPR Comparison
Compare INO & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- JSPR
- Stock Information
- Founded
- INO 1979
- JSPR 2018
- Country
- INO United States
- JSPR United States
- Employees
- INO N/A
- JSPR N/A
- Industry
- INO Medical/Dental Instruments
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INO Health Care
- JSPR Health Care
- Exchange
- INO Nasdaq
- JSPR Nasdaq
- Market Cap
- INO 75.4M
- JSPR 82.4M
- IPO Year
- INO 1998
- JSPR N/A
- Fundamental
- Price
- INO $2.24
- JSPR $5.96
- Analyst Decision
- INO Buy
- JSPR Strong Buy
- Analyst Count
- INO 6
- JSPR 12
- Target Price
- INO $17.00
- JSPR $64.44
- AVG Volume (30 Days)
- INO 739.9K
- JSPR 444.8K
- Earning Date
- INO 03-05-2025
- JSPR 03-03-2025
- Dividend Yield
- INO N/A
- JSPR N/A
- EPS Growth
- INO N/A
- JSPR N/A
- EPS
- INO N/A
- JSPR N/A
- Revenue
- INO $203,413.00
- JSPR N/A
- Revenue This Year
- INO N/A
- JSPR N/A
- Revenue Next Year
- INO $1,970.14
- JSPR N/A
- P/E Ratio
- INO N/A
- JSPR N/A
- Revenue Growth
- INO N/A
- JSPR N/A
- 52 Week Low
- INO $1.74
- JSPR $4.55
- 52 Week High
- INO $14.75
- JSPR $31.01
- Technical
- Relative Strength Index (RSI)
- INO 54.46
- JSPR 34.64
- Support Level
- INO $1.82
- JSPR $4.55
- Resistance Level
- INO $2.31
- JSPR $6.55
- Average True Range (ATR)
- INO 0.14
- JSPR 0.53
- MACD
- INO 0.05
- JSPR 0.49
- Stochastic Oscillator
- INO 83.17
- JSPR 56.18
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.